Innate Pharma S.A. (NASDAQ:IPHA) Sees Significant Growth in Short Interest

Innate Pharma S.A. (NASDAQ:IPHA) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 461,400 shares, a growth of 199.2% from the February 13th total of 154,200 shares. Based on an average trading volume of 677,300 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.8% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $11.50 price target on shares of Innate Pharma in a research report on Thursday, February 6th.

Innate Pharma Stock Performance

Shares of IPHA stock opened at $1.95 on Friday. Innate Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $3.51. The business has a fifty day simple moving average of $1.94 and a 200-day simple moving average of $1.96.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.